• Asian Journal of Business Environment
• /
• 제11권4호
• /
• pp.39-45
• /
• 2021

Purpose: This study is designed to investigate the extent and nature of climate change disclosure of listed pharmaceutical companies of Bangladesh. Research design, data and methodology: In order to perform this research, a content analysis methodology is used. A climate change disclosure index is constructed to examine 12 different climate change disclosure issues. Information is collected from the annual reports of 29 pharmaceutical companies listed on the Dhaka Stock Exchange for the year 2019. Results: This study finds that only 48.28% of the sample companies provided disclosure on at least one issue regarding climate change. 'Energy savings' is the mostly disclosed issue whereas 'Pollution control expenditure', 'Biodiversity conservation initiatives' are the least disclosed issues. Research implication: This study concludes 64.29% of the companies examined, use less than five sentences for climate change disclosure, which depicts unsatisfactory disclosure practices regarding climate change issues. Study findings would be helpful for different industries of Bangladesh to implement efficient climate change reporting Practice. Future studies can be conducted on other industries to obtain more comprehensive result.

• 한국경영과학회지
• /
• 제42권3호
• /
• pp.35-49
• /
• 2017

The main objective of this paper is to empirically analyze the efficiency effects of mergers on Korean pharmaceutical firms and suggests managerial or policy implications for managers or policy makers. This study selects non-merging control firms close to the size of merging firms, as well as a set of merging firms, and measures the effects of mergers on efficiency three years before and after the merger using the non-parametric data envelopment analysis (DEA) method. To compare the differences of efficiency means among several groups, Wilcoxon rank sum test or Wilcoxon signed rank test is used. It showed that the long-term effects after the merger appeared partially. Furthermore, it was observed that there was no difference statistically in the efficiency between merging and non-merging firms. Also, there was no difference statistically in the efficiency between the pre- and post-merger periods. In conclusion, there was not any observed synergy effect through group (or affiliated) mergers between affiliates or related mergers for Korean pharmaceutical firms.

• Bulletin of the Korean Chemical Society
• /
• 제35권7호
• /
• pp.2210-2212
• /
• 2014

• 한국산학기술학회논문지
• /
• 제19권5호
• /
• pp.389-398
• /
• 2018

상호인정협약(MRA)은 무역기술장벽(TBT) 극복을 위한 WTO 틀 내의 중요한 정책수단이다. MRA의 경제적 효과와 관련된 연구는 대부분 인터뷰와 간단한 설문조사를 통해 그 효과를 확인하거나 MRA체결을 통해 면제되는 제품의 심사비용이 명확하고 계량분석이 가능한 데이터가 축적된 정보통신산업 등에서 제한적으로 계량 분석을 통해 비용절감 효과와 수출에 미치는 영향을 제시한다. 이러한 연구결과는 모두 MRA 체결이 긍정적 경제효과를 가져오는 것으로 분석되었다. 그러나 제약 산업의 MRA체결에 대해 직접 경제적 효과를 분석한 연구는 없다. 따라서 본 논문에서는 EFTA와의 GMP 실사 면제 MRA체결의 경제효과를 비시장재의 가치 추정 방법인 조건부가치평가법(CVM)을 통해 분석하였다. 먼저 제약 기업을 대상으로 EFTA권역과의 MRA 체결 의의와 효과를 설명하고, 가상의 시장을 설정하여 GMP 실사 면제에 대한 연회비 형태의 지불의사를 이중경계양분형질문을 통해 조사하였다. 이를 Hanemann(1984)이 제시한 효용차이모형을 통해 중간값 WTP와 절단된 평균 WTP를 산출하였고, 이를 바탕으로 전체기업의 경제효과를 산출한 결과 연간 최소 70.3억에서 최대 약 158억의 경제적 효과가 있는 것으로 분석되었다.

• 한국산학기술학회논문지
• /
• 제12권3호
• /
• pp.1270-1277
• /
• 2011

제약산업은 연구개발 비중이 높은 지식기반산업으로 우수한 연구개발 인력에 기초한 연구 역량이 국가경쟁력의 핵심요소로 작용한다. 연구개발 역량이 우수한 국가가 세계시장을 선도하고, 높은 기술력만 있으면 세계 시장지배를 통해 고도성장이 가능한 분야다. 특히 제약분야의 연구개발 역량 강화를 위해서는 적정 규모의 연구인력 확보가 선결되어야할 과제다. 본 연구는 전문가 델파이 기법을 이용하여 제약분야의 연구개발 인력 수급 현황(2007년)과 함께 미래(2017년)의 인력수급 현황에 대해서 조사 분석하였다. 본 연구의 결과를 정리하면 다음과 같다. 첫째, 2007년 현재 제약 산업 분야의 연구개발 인력은 적정규모에 비해 약 5,600명 부족한 것으로 평가된다(부족률: 약 18.1%). 둘째, 향후 2017년에는 필요 연구개발 인력 대비 공급이 약 13,500명 부족할 것으로 전망되어 연구인력 수급 불균형은 향후 더 심화될 것으로 전망된다. 본 연구결과는 정부의 제약 분야에 대한 R&D 인력수급 정책의 변화가 없을 경우 향후 인력 수급에 심각한 차질(부족 현상)이 예상됨을 보여주는 만큼 합리적이고 체계적인 연구인력 수급 정책마련이 시급하게 필요함을 시사해 주고 있다.

• 보건의료산업학회지
• /
• 제9권4호
• /
• pp.157-169
• /
• 2015

Objectives : The aim of this study was to investigate the effect of various Republic of Korea policies, including the medicine cost rationalization policy implemented By investigating the management strategy/performance changes of the industry caused by such policies. Methods : Pharmaceutical companies listed on the national stock exchange and the KOSDAQ were examined for 10 years from 2004 to 2013. Their financial statements were collected and market changes before and after drug price policy implementations were compared. Results : From the result of this research, among the medicine related policies, the drug price rationalization policy was found to have a significant effect on business management strategies in terms of safety, profitability and growth potential after its implementation. After the drug pricing transparency policy was implemented, management strategies were affected significantly in terms of safety and profitability. Conclusions : As a result, all of the medicine related policies were found to have regulatory effects. Based on these findings, implications, research limitations and future study plans are presented.

• 보건의료산업학회지
• /
• 제13권3호
• /
• pp.105-114
• /
• 2019

Objectives: This study aimed to provide a comprehensive analysis of the relationship between the service quality of the Korea Health Industry Development Institute (KHIDI), along with the utilization of and customer satisfaction with its export supporting program, and the export performance of Korean pharmaceutical companies. Methods: An online and offline survey was conducted on Korean pharmaceutical companies that have used the export supporting program provided by KHIDI. Data on the service quality of KHIDI, utilization of and customer satisfaction with the export supporting program, and company export performance were collected via survey. Results: Results indicated that systemizing and reliability service factors of the export supporting program have a significant impact on customer satisfaction, and customer satisfaction has a significant impact on utilization of the export supporting program. Furthermore, customer satisfaction and utilization of the program have a significant impact on company expectations regarding future export performance. Conclusions: As a result, service quality, utilization, and customer satisfaction were found to affect Korean pharmaceutical company's expectations regarding their future export performance. The results of this study can significantly impact the development of export supporting programs.

• 디지털융복합연구
• /
• 제20권5호
• /
• pp.423-432
• /
• 2022

본 연구에서는 의약업 기업에 대한 경영효율성 분석을 실시한다. 이는 COVID-19 인해 치료제 개발로 인해 의약업은 기업가치는 상승하지만 치료제 개발이 지체되고 해외시장의 개척은 COVID-19 인한 국경봉쇄로 인해 어려움을 겪고 있다. 따라서 이들 기업의 경영효율성이 분석을 실시하여 각 기업들이 효율적인 경영 방안을 제시하고자 한다. 연구방법으로는 유가증권 의약업을 대상으로 자료포락분석을 이용하여 비효율적인 기업이 효율적인 프론티어 도달하기 위한 벤치마킹 할 수 있는 기업의 참조집합을 확인하고, 투사값을 제시하고자 한다. 분석결과, 코로나 이전과 이후의 경영효율성은 큰 차이를 보이지 않았으나, 특정기업은 경영효율성이 하락함을 확인하였다. 본 연구를 통해 기업의 생존경쟁력과 경영전략을 판단 할 수 있으며, 더 나아가 지속적인 성장과 경쟁력 제고를 위한 방안을 제시하였다.

• Journal of Pharmaceutical Investigation
• /
• 제23권4호
• /
• pp.231-254
• /
• 1993

These days, it is not uncommon that a same kind of drug is circulated globally. However, the qualities of excipients used in the same drug have to be sometimes different depending on the different requirements in the qualities stipulated by each country. For a supplier of pharmaceutical excipients, it is generally necessary to carry out different tests on the same kind of testing criteria depending on the country of destination. Thus, the discrepancies between compendium requirements of pharmaceutical excipients create severe problems in various area of industrial activities. The decision of the United States Pharmacopoeia, European Pharmacopoeia and Japanese Pharmacopoeia Commissions to harmonize the requirements is a unique chance for the industries to overcome these problems. On the other hand, discrepancies of general test methods and requirements in each monograph of pharmaceutical excipient between the compendia valid at present are in most cases extensive. Consequently their harmonization needs a lot of detailed work requiring strong support from the industry. Based on these circumstances, pharmaceutical excipients councils have been established first in U.S.A. and successively in Europe and in Japan to contribute to the harmorization process. We should like to review here the progress since the Orlando Conference in 1991 and comment about the matters at issue with regard to the international harmonization of pharmaceutical excipients.

• 한국병원경영학회지
• /
• 제5권1호
• /
• pp.24-39
• /
• 2000

This paper aims to analyze the effects that marketing mix variables have on the marketing performance of pharmaceutical manufacturers. It examines how product characteristics, price, marketing channel and promotion effort influence the sales and market share of anti-ulcer drugs in the markets for clinics and hospitals separately. Empirical results from 29 products of anti-ulcer drugs show that sales in hospitals are affected by the profit per prescription to the physician, brand name drugs relative to generics, and the age of ingredients since its introduction to the markets. Profit per prescription to the hospital, relative price, age of ingredients and promotion effort have positive effects on the market share.